Skip to main content
Top
Published in: Familial Cancer 1/2011

01-03-2011

Colorectal cancer: no longer the issue in familial adenomatous polyposis?

Authors: Daniel C. Gibbons, Ashish Sinha, Robin K. S. Phillips, Susan K. Clark

Published in: Familial Cancer | Issue 1/2011

Login to get access

Abstract

Familial adenomatous polyposis (FAP) is a dominantly inherited colorectal cancer (CRC) syndrome with an untreated lifetime prevalence of CRC close to 100% and extracolonic manifestations (ECM) of increasing clinical significance. This study examined the effect of systematic callup and prophylactic colectomy on FAP survival. Patients diagnosed, treated and followed-up at our institution were analysed. ‘Callups’ were those identified via the callup system; ‘probands’ were those identified by other means. Proportions were analysed by Chi-squared or Fischer’s exact test. Mortality rates were indirectly standardised to the UK population. Survival curves from birth were estimated by Kaplan–Meier. A total of 439 patients (293 callups, 146 probands) were analysed. Crude mortality rates (CMRs) of callups and probands were 4.85 per 1,000 person years (PY) and 9.71 per 1,000 PY, respectively—a rate ratio of 0.50 (95% CI 0.34–0.72, P = 0.0001). The standardised mortality ratio (SMR) of callups was non-significantly lower than probands (4.12 vs. 4.70). Callups experienced non-significantly lower age-band specific SMR up to 45 years. More probands died of CRC (42.4 vs. 22.5%, P = 0.025), whereas more callups died of ECM (30.6 vs. 13.4%, P = 0.027). Median survival was 64 years for callups and 60 years for probands; survival curves did not differ significantly (P = 0.253). The crude mortality rate of callups is approximately half that of probands. As fewer callups die of CRC, a greater proportion die of ECMs. Callups experienced non-significantly reduced mortality up to 45 years. Whilst the FAP callup system reduces CRC risk, mortality attributable to ECMs needs to be addressed.
Literature
2.
go back to reference Cruz-Correa M, Giardiello FM (2003) Familial adenomatous polyposis. Gastrointest Endosc 58(6):885–894CrossRefPubMed Cruz-Correa M, Giardiello FM (2003) Familial adenomatous polyposis. Gastrointest Endosc 58(6):885–894CrossRefPubMed
3.
go back to reference Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125CrossRefPubMed Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125CrossRefPubMed
4.
go back to reference Kinzler KW, Vogelstein B (2002) Colorectal tumors. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw Hill, New York Kinzler KW, Vogelstein B (2002) Colorectal tumors. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw Hill, New York
5.
go back to reference Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, Friedl W (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58CrossRefPubMed Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, Friedl W (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58CrossRefPubMed
6.
go back to reference Laken SJ, Papadopoulos N, Petersen GM, Gruber SB, Hamilton SR, Giardiello FM et al. (1999) Analysis of masked mutations in familial adenomatous polyposis. Proc Natl Acad Sci USA 96(5): 2322–2326 Laken SJ, Papadopoulos N, Petersen GM, Gruber SB, Hamilton SR, Giardiello FM et al. (1999) Analysis of masked mutations in familial adenomatous polyposis. Proc Natl Acad Sci USA 96(5): 2322–2326
7.
go back to reference Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P et al (2003) Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21(9):1698–1707CrossRefPubMed Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P et al (2003) Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21(9):1698–1707CrossRefPubMed
8.
go back to reference Phillips RKS, Clark SK, Wolff BG, Fleshman JW, Beck DE, Pemberton JH et al. (2007) Polyposis syndromes. In: The ASCRS textbook of colon and rectal surgery. Springer-Verlag, New York Phillips RKS, Clark SK, Wolff BG, Fleshman JW, Beck DE, Pemberton JH et al. (2007) Polyposis syndromes. In: The ASCRS textbook of colon and rectal surgery. Springer-Verlag, New York
9.
go back to reference Debinski HS, Love S, Spigelman AD, Phillips RK (1996) Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110(4):1028–1030CrossRefPubMed Debinski HS, Love S, Spigelman AD, Phillips RK (1996) Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110(4):1028–1030CrossRefPubMed
10.
go back to reference Knudsen AL, Bisgaard ML, Bülow S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2(1):43–55 Knudsen AL, Bisgaard ML, Bülow S (2003) Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2(1):43–55
11.
go back to reference Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S (1996) Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 39(4):384–387CrossRefPubMed Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S (1996) Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 39(4):384–387CrossRefPubMed
12.
go back to reference Bülow S, Bülow C, Nielsen TF, Karlsen L, Moesgaard F (1995) Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the danish polyposis register. Scand J Gastroenterol 30(10):989–993 Bülow S, Bülow C, Nielsen TF, Karlsen L, Moesgaard F (1995) Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the danish polyposis register. Scand J Gastroenterol 30(10):989–993
13.
go back to reference Heiskanen I, Luostarinen T, Järvinen HJ (2000) Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35(12):1284–1287CrossRefPubMed Heiskanen I, Luostarinen T, Järvinen HJ (2000) Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35(12):1284–1287CrossRefPubMed
14.
go back to reference Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704–713CrossRefPubMed Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704–713CrossRefPubMed
Metadata
Title
Colorectal cancer: no longer the issue in familial adenomatous polyposis?
Authors
Daniel C. Gibbons
Ashish Sinha
Robin K. S. Phillips
Susan K. Clark
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9394-x

Other articles of this Issue 1/2011

Familial Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine